Compared to other insulin delivery approaches, the development of microfluidic technologies for inhaled insulin is rare, possibly owing to previous finding that use of inhaled insulin is positively correlated with lung cancer [199, 200]. The gene discussed is INS; the disease is lung carcinoma.